Τόμος 22 (2004) – Τεύχος 3 – Άρθρο 1 – Επιθεώρηση Κλινικής Φαρμακολογίας και Φαρμακοκινητικής-Ελληνική Έκδοση – Volume 22 (2004) – Issue 2 – Article 1 – Epitheorese Klinikes Farmakologias και Farmakokinetikes-Greek Edition

Βασίλης Α. Κόκκας, Κωνσταντίνος Λ. Παπαδόπουλος

Εργαστήριο Φαρμακολογίας και Β΄καρδιολογική Κλινική, Τμήμα Ιατρικής, Αριστοτέλειο Πανεπιστήμιο, Θεσσαλονίκη, Ελλάς

Β.Α. Kokkas, C.L. Papadopoulos

Departments of Pharmacology and 2^nd Cardiology, Medical School, Aristotle University, Thessaloniki, Greece

2. Τρακατέλλης Α.: Βιοχημεία. Θεσσαλονίκη,1981

3. Guyton A., Hall J.: Textbook of Medical Physiology. W. B. Saunders Company, London, 1996

4. Lafontan M., Berlan M.: Do regional differences in adipocyte biology provide new pathophysiological insights. Trends Pharmacol. Sci. 24:276-282 (2003)

5. Trayhurn P., Beattie J.: Physiological role of adipose tissue. White adipose tissue as an endocrine and secretory organ. Proc. Nutr. Soc. 60: 329-339 (2001)

6. Schling P., Loffler G.: Cross-talk between adipose tissue cells. Impact on physiology. N. Physiol. Sci. 17: 99-104 (2002)

7. Garenc C.: The alpha2-adrenergic receptor gene and body fat content and distribution. The Heritage family study. Mol. Med. 8: 88-94 (2002)

8. Πλέσσας Σ., Πλέσσας Χ.: L-καρνιτίνη. Ο ρόλος της στην Ιατρική. Επιθ. Κλιν. Φαρμακολογίας Φαρμακοκιν. 13: 11-64 (1996)

9. Laschi R.: L-carnitine and ischemia. Fondazione Sigma-Tau 1987

10. Glatz J., Laiken H., van Nieuwenhoven, van der Vusse G.: Molecular mechanism of cellular uptake and intracellular translocation of fatty acids. Prostaglandine Leukot. Essent. Fatty Acids 57:3-9 (1997)

11. Murphy G., Holder J.: PPAR-γ agonists. Therapeutic role in diabetes, inflammation and cancer. Trends Pharmacol. Sci. 21: 469-474 (2000)

12. Eaton S., Bartlett K.: Mammalian mitochondria beta- oxidation. Biochem. J. 320: 345-357 (1996)

13. Treem W., Stanley C., Finegold D., Hale D., Coates P.: Primary carnitine deficiency due to a failure of carnitine transport in kidney, muscle and fibroblasts. N. Engl. J. Med. 319: 1331-1336 (1988)

14. Ushikubo S., Aoyama T., Souri M.: Formation of the enzyme complex in mitochondrial trifunctional protein deficiency. Formation of the enzymwe complex is important for stabilization of both alpha and beta subunits. Am. J. Hum. Genet. 58: 979-988 (1996)

15. Brown R., Mendell J.: Muscular dystrophies and other muscle diseases. In: (Braunwald E., et al., eds) Harrison’s Principles of Internal Medicine. Pp. 2529-2540, Mc Graw-Ηill Med. Publ. Div., New York, 2001

16. Power G.: Dietary fatty acids influence the activity and metabolic control of mitochondrial carnitine palmitoyl-transferase I in rat heart and skeletal muscle. J. Nutr. 127: 2142-2150 (1997)

17. Van Bilsen M., De Vries J., Van der Vusse G.: Long-term effects of fatty acids on cell viability and gene expression of neonatal cardiac myocytes. Prostaglandins Leuko.t Essent Fatty Acids 57: 39-45 (1997)

18. Van der Lee K., Vork M., De Vries J.: Long-chain fatty acid induced changes in gene expression in neonatal cardiac myocytes. J. Lipid Res. 41: 41-47 (2000)

19. Gotto A., Pownall H. (eds): Manual of Lipid Disorders. Lippincott and Wilkins, Philadelphia, 2003

20. Bishop-Bailey D.: Peroxisome proliferator-activated receptors in the cardiovascular system. Br. J. Pharmacol. 129: 823-834 (2000)

21. Gervois P., Torra I., Fruchart J., Staels B.: Regulation of lipid and lipoprotein metabolism by PPAR activators. Clin. Chem. Lab. Med. 38: 3-11 (2000)

22. Torra I.P., Genois Ph., Staels B.: Peroxisome proliferator–activated receptor alpha in metabolic disease, inflammation, atherosclerosis and aging. Curr. Opin. Lipidol 10: 151-159 (1999)

23. Auboeuf D., Rieusset J., Fajas L., Vallier P., Frering V., Riou J.P.: Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-α in humans. No alteration in adipose tissue of obese and NIDDM patients. Diabetes 46:1319-1327 (1997).

24. Fajas L., Fruchart J.-C., Auwerx J.: Transcriptional control of adipogenesis. Curr. Opin. Cell Biol. 10:165-173 (1998).

25. Spiegelman B.: PPAR-gamma; adipogenic regulator and thiazolidinedione receptor. Diabetes 47: 507-514 (1998)

26. Κόκκας B., Παπαδόπουλος Κ.Λ., Παπαδόπουλος Π.Κ.: PPAR–υποδοχείς και αντιαθηρωσκληρωτικοί μηχανισμοί. Επιθ. Κλιν. Φαρμακολ. Φαρμακοκιν. 18: 11-17 (2000)

27. Chineti G., Fruchart J.C., Staels B.: Peroxisome proliferator-activeted receptors. New targets for the pharmacological modulation of macrophage gene expression and function. Curr. Opin. Cell Biol. 14: 459-468 (2003).

28. Zhang B., Marcus S., Sajjadi F.: Identification of a peroxisome proliferator-responsive element upstream of the gene encoding rat peroxosomal enoyl-CoA hydra-tase/3-hydroxyacyl-CoA dehydrogenase. Proc. Natl. Acad. Sci. USA 89: 7541-7545 (1992)

29. Kenno K., Steverson D.: Lipolysis in isolated myocardial cells from diabetic rat hearts. Am. J. Physiol. 249: H1024-1034 (1985)

30. Orrenius S., McConkey D., Bellomo G., Nicotera P.: Role of Ca²⁺ in toxic cell killing. Trends Pharmacol. Sci. 10: 281-285 (1989)

31. Ashavaid T., Colvin R., Messinco F., MacAlister T.: Effects of fatty acids on Na/Ca exchange in cardiac sarcolemmal membranes. J. Mol. Cell Cardiol 17: 851-861 (1985)

32. Corr P., Gross R., Sobel B.: Amphipathic metabolites and membrane dysfunction in ischemic myocardium. Circ. Res. 55: 135-154 (1984)

33. Van der Vusse G., Roemen T., Prinzen F., Coumans W.: Uptake and tissue content of fatty acids in dog myocardium under normoxic and ischemic conditions. Circ. Res. 50: 538-546 (1982)

34. Li Q., Altschuld R., Stokes B.: Myocyte deenergization and intracellular free calcium dynamics. Am. J. Physiol. 255: C162-168 (1988)

35. Παπαγιάννης Ι., Παπαδόπουλος Κ.Λ.: L-καρνιτίνη. Αρρυθμίες κατά την ισχαιμία. Επιθ. Κλιν. Φαρμακολογίας Φαρμακοκιν. 10: 164-172 (1992)

36. Κόκκας Β.: Θέματα Μοριακής Φαρμακολογίας. University Studio Press, Θεσσαλονίκη, 1999

37. De Windth L., Reneman R., Van der Vusse G, Van Bilsen M.: Phospholipase A2-mediated hydrolysis of cardiac phospholipids. The use of molecular and transgenic tecvhiques. Mol. Cell Biochem. 180: 65-73 (1998)

38. Post J., Langer G., Op dem Kamp J., Verkleij A.: Phospholipid asymmetry in cardiac sarcolemma. Analysis of intact cells and “gas-dissected” membranes. Mol. Cell Biochem. 943: 256-266 (1988)

39. Lips D., De Windth L., Kraaij D., Doevendans P.; Molecular determinants of myocardial hypertrophy and failure. Alternative pathways for beneficial and maladaptive hypertrophy. Eur. Heart J. 24: 883-896 (2003)

40. Van Bilsen M., Van der Vusse G., Willemsen P., Coumans W.: Lipid alterations in isolated working rat hearts during ischemia and reperfusion. Its relation to myocardial damage. Circ. Res. 64: 304-314 (1989)

41. Magishi K., Kimura J., Kubo Y., Abiko Y.: Exogenous lysophosphatidylcholine increases nonselective cation current in guinea-pig ventricular myocytes. Pflugers Arch. 432: 345-350 (1996)

42. Marcus R., Coulston A.: Water soluble vitamins. In: (Hardman J. et al., eds) Goodman and Gilman’s. The Pharmacological basis of therapeutics. Pp. 1753-1771, McGraw-Hill Med. Publ. Company. New York, 2001

43. Dobsak P., Courderot-Masuyer C., Zeller M.: Anti-oxidant properties of pyruvate and protection of the ischemic rat heart during cardioplegia. J. Cardiovasc. Pharmacol. 34: 651-659 (1999)

44. Rosen P., Reinauer H.: Inhibition of carnitine palmitoyltransferase I by phenylalkyloxiranecarboxylic acid and its ingluence on lipolysis and glucose metabolism in isolated perfused hearts of streptozotocin-diabetic rats. Metabolism 33: 177-185 (1984)

45. Stanley W., Marzili M.: Metabolic therapy in the treatment of ischemic heart disease. The pharmacology of trimetazidine. Fund. Clin. Pharmacol. 17: 133-145 (2003)

46. Wolff A., Rotmensch H., Stanley W., Ferrari R.: Metabolic aproaches to the treatment of ischemic heart disease. The clinician’s perspective. Heart Failure Reviews 7: 187-203 (2002)

47. Rupp H., Zarain-Herzberg A., Maisch B.: The use of partial fatty acid oxidation inhibitors for metabolic therapy of angina pectoris and heart failure. Hertz 27: 621-636 (2002)

48. Marzilli M.: Cardioprotective effects of trimetazidine. A review. Curr. Med. Res. Origine 19: 661-672 (2003)

49. Singh R., Niaz M., Sharma J.: Randomized double-blind, placebo-controlled trial of fish oil and mustard oil in patients with suspected acute myocardial infraction. The Indian experiment of infract survival-4. Cardiovasc. Drugs Ther. 11: 485-491 (1997)

50. Siscovick D., Raghunathan T., King I.: Dietary intake and cell membrane levels of long-chain n-3polyunsatured fatty acids and risk of primary cardiac arrest. JAMA 274: 1363-1367 (1995)

51. Tora I., Gervous Ph., Staels B.: Peroxisome proliferator-activated receptor alpha in metabolic disease, inflammation, atherosclerosis and aging. Cur. Opin. Lipidol 10: 151-159 (1999)

52. Emery J., Ohlstein E., Jaye M.: Therapeutic modulation of transcription factor activity. Trends Pharmacol. Sci. 22: 233-239 (2001)

53. Tugwood J., Isseman I., Anderson R., Bundell K.: The mouse peroxisome proliferator activated receptor recognizes a response element in the 5+flanking sequence of the rat acylCoA oxidase gene. EMBO J. 11: 433-439 (1992)

54. Fruchart J., Duriez P. and Staels B.: Peroxisome proliferator-activated receptor-alpha activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis. Curr. Opin.Lipid.10: 245-257 (1999)

55. Fruchart J., Duriez P., Staels B.: Molecular mechanism of action of the fibrates. J. Soc. Biol. 193: 67-75 (1999)

56. Baily G.: Potential new treatments for type 2 diabetes. Trends Pharmacol. Sci. 21: 259-264 (2000)